Reached Strategic Cooperation, And Jointly Built Synthetic Biological Polypeptide Project Intelligent Production Line

Xiushi Biopharma and Lechun Biotech have reached a strategic cooperation to jointly build an intelligent production line for synthetic biology peptide projects

Wang Feng, CEO of LePure Biotech

"In recent years,LePure Biotech has been continuously optimizing its core competitiveness and actively seeking technological collaborations, aiming to drive innovation and development in the field of biotechnology through partnerships with outstanding companies from different sectors. Against the backdrop of the country's emphasis on technological advancement and industrial development, more and more alumni from Huazhong University of Science and Technology are choosing entrepreneurship. Together, we are leveraging our technological advancements and innovations to bring about new industrial opportunities, facilitating industrial upgrades and providing our generation with a valuable chance. The LePure Biotech team embodies the university motto of 'diligence and pragmatism.'

I believe that the foundation of our collaboration with LePure Biotech lies in their diligent and pragmatic team, as well as their advanced synthetic biology process technology. We are honored to have the opportunity to work with LePure Biotech in creating intelligent synthetic biology engineering. We hope to leverage LePure Biotech's capabilities, talents, and resources, in conjunction with our own, to jointly research purification and fermentation processes, ensuring that each step is implemented in terms of drawings, equipment, and consumables. This is to realize the vision of mutual assistance, cooperation, and learning among Huazhong University alumni, as proposed by Mr. Wu. We also look forward to this collaboration bringing about more technological breakthroughs and market achievements, collectively driving the global life and health industry forward."

Wu Yinsong CEO of XiuShi Biotech

"LePure Biotech is a leading enterprise with a complete set of solution tools for the upstream process of biomedicine in China, serving more than 700 biopharmaceutical companies at home and abroad. We are very pleased to have the full trust of our LePure Biotech partners, and will jointly develop and build a more efficient polypeptide drug process chain with synthetic biology technology as the core, to achieve a comprehensive and highly leading technical solution from the upstream microbial lean fermentation to the downstream purification, and finally to the raw materials or preparations.

"As a BIOTECH company, LePure Biotech and Xiushi Biotech are positioned in different segments of the industry chain. Both parties will share their respective experiences in the upstream and downstream, which will be a valuable process of mutual empowerment and enhancement. I believe that this collaboration will definitely achieve great results. This partnership opens up new opportunities, as both sides will focus on the important industry tracks of synthetic biology and peptide drugs with the same vision. This is a challenging journey, and I believe it will lead to even broader industrial prospects."

During the signing ceremony, leaders from the Beigao New Area of Nantong City made speeches and expressed high recognition for the strong alliance between the two companies. With the conclusion of the ceremony, Xiu Shi Biotech and LePure Biotech officially established a strategic cooperation relationship. The powerful combination of Xiu Shi Biotech and LePure Biotech will undoubtedly inject strong momentum into the construction and development of an intelligent production line for synthetic biology peptide projects. Both parties will take this cooperation as an opportunity to contribute more high-quality and innovative solutions to the fields of synthetic biology and peptide drugs, promote the rapid development of China's biopharmaceutical industry, and make greater contributions to the health of the people.

Following the signing ceremony, representatives from both sides visited the Beigao New Area. The Beigao New Technology Industrial Development Zone in Nantong City, Jiangsu Province, is located in the core area of the northern wing of the main urban area of Nantong City. It was jointly established by Nantong City and Shanghai Jing'an District in 2010 and was approved by the Jiangsu Provincial People's Government in September 2018, with a jurisdiction area of 68.08 square kilometers. The Beigao New Area is positioned for development as a "leading area for high-tech industries, a pioneer area for innovation, and a demonstration area for cooperation between Shanghai and Nantong." Focusing on the field of life and health, it centers around new drug research and development, innovative medical devices, precision medicine, genetic testing, in vitro diagnostics, and special dietary drugs as the main chain directions. Through a series of common and individual policies related to industry, technology, and talent, the area conducts precise investment attraction and support. In the evaluation of high-quality development of high-tech zones in the province, it ranks among the top ten provincial-level high-tech zones in the province and ranks second in sustainable development level among high-tech zones in the province.

Shanghai LePure Biotech Co., LTD was established in 2011. Through external growth strategies, it has integrated excellent brands such as GE Healthcare, Kangsheng Biotech, and Thermo Fisher Scientific. Its current business scope covers various application scenarios including cell culture, filtration purification, disposable systems, and industrial anti-pollution clean solutions. It has now become a widely recognized top supplier in the pharmaceutical industry's upstream process chain.

"Xiushi Biopharmaceutical (Nantong) Co., Ltd. was established in 2020, with a core team composed of technical experts in pharmaceutical engineering, fermentation engineering, and protein engineering. Leveraging rich practical experience in the field of biomanufacturing, we provide industry partners with innovative and highly attractive solutions for the biosynthesis of peptide drugs. Our unique innovative biosynthesis strategy has been successfully validated on various short peptides and complex cyclic peptides at scale, offering production capacity and cost advantages beyond current traditional biological and chemical synthesis methods. This has led to development collaboration orders from numerous well-known pharmaceutical companies and CDMO enterprises. Xiushi Biopharmaceutical is committed to helping partners stay ahead in the discovery and production process development of peptide drugs through innovative biosynthesis technology."